Clinical Trial Update: The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4) [Phase 3]

View source ↗

Summary

Phase 3 trial ENDURANCE-4 evaluated ABT-493/ABT-530 for chronic hepatitis C virus infection genotypes 4, 5, or 6; results completed with posted data in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-493/ABT-530 (glecaprevir/pibrentasvir)

Snippet

Sponsor: AbbVie | Conditions: Hepatitis C Virus | Phase 3 | Status: COMPLETED | Results posted: 2017-09-14